CJC-1295 with DAC has a 7-day half-life; without DAC, it lasts 30 minutes. The differences in pulsatility, IGF-1 response, side effects, and labs to track.
# CJC-1295 With DAC vs Without DAC: The Honest Comparison (2026) CJC-1295 comes in two forms with very different pharmacology. Knowing which one you're actually running matters because the IGF-1 response, side effect profile, dosing schedule, and bloodwork timing are not the same. Most people who buy "CJC-1295" don't realize they're choosing between two pharmacologically distinct compounds. This is the honest breakdown. We'll cover what each variant actually does, when each one is the right choice, what to track, and what to expect.
If you didn't specifically buy "CJC-1295 with DAC" or see a 7-day dosing protocol, you're almost certainly running no DAC.
The Drug Affinity Complex is a maleimidopropionic acid linker that binds CJC-1295 to serum albumin. Albumin has a multi-day half-life in the bloodstream. By covalently linking the peptide to albumin, the DAC extends the active half-life from ~30 minutes to ~7 days.
That's the entire mechanism. One small chemical addition turns a short-acting GHRH analog into a long-acting one.
The downstream pharmacology is profoundly different.
Half-life: ~30 minutes.
Pharmacology: Mimics the body's natural GHRH pulses. When injected, it triggers a sharp, time-limited GH release that resembles physiologic secretion. By the time it clears, the pituitary is ready to respond to the next pulse.
Standard protocol: 100-200mcg subcutaneously, 1-3x daily, paired with Ipamorelin (100-200mcg) for synergistic GH pulse amplification. Most commonly dosed at wake and pre-bed on empty stomach.
IGF-1 response: Moderate, sustained elevation of ~1.5-2x baseline at 6-week mark. Predictable curve in published research.
Side effect profile: Minimal. Pulsatile dosing avoids the desensitization risk that comes with sustained GH elevation. Cortisol and prolactin stay relatively stable when paired with Ipamorelin (which doesn't trigger them either).
Bloodwork to track:
Half-life: ~7 days.
Pharmacology: Once injected, GHRH analog stays bioactive for a full week, producing sustained low-grade elevation of GH rather than discrete pulses. The pituitary doesn't get the natural rest periods between pulses.
Standard protocol: 2mg subcutaneously, 1-2x weekly. Some advanced protocols use 1mg twice weekly to slightly normalize the rhythm.
IGF-1 response: Larger initial elevation (often 2.5-3.5x baseline at 6 weeks), but the response can plateau or partially desensitize over months due to non-physiologic continuous stimulation.
Side effect profile: Higher than no DAC.
Bloodwork to track: Heavier monitoring load.
Choose no DAC if:
Choose with DAC if:
For most users, no DAC is the answer. The pulsatile pattern is closer to what the body evolved for, the side effect profile is gentler, and the dose-response relationship is more predictable.
Mistake 1: Buying CJC-1295 and not knowing which form. Always confirm before purchase. "CJC-1295" without specifying "no DAC" or "with DAC" is ambiguous. Reputable compounding pharmacies will label clearly.
Mistake 2: Running with-DAC at no-DAC frequency. Injecting CJC-1295 with DAC daily produces dangerous sustained over-stimulation. Once-or-twice weekly is the protocol.
Mistake 3: Skipping the IGF-1 baseline. Both forms work by elevating IGF-1. Without a baseline draw before starting, you can't measure your actual response. A pre-cycle IGF-1 panel costs $30-50 at most labs.
Mistake 4: Stacking both forms simultaneously. Some users layer with-DAC + no-DAC + Ipamorelin thinking more is more. This produces unpredictable IGF-1 spikes and is not supported by any published research.
Mistake 5: Not pairing no-DAC with Ipamorelin. No-DAC alone produces a smaller GH pulse than the synergistic pulse you get from pairing with a GHRP. Almost every standard protocol pairs them.
Whether you're running no DAC or with DAC, here's the bloodwork schedule:
Pre-cycle (Week -2 to -1):
Mid-cycle (Week 4-6):
End-cycle / quarterly (Week 12):
If you run either form of CJC-1295, MyProtocolStack auto-flags the markers above on your dashboard. The biomarker detail view shows your IGF-1 trend with the cycle window shaded — so you can see exactly which weeks the elevation happened and whether it correlated with your protocol start. Optimal range bands are personalized to your age and active protocol type (IGF-1 optimal range on a GH-secretagogue cycle is different from baseline).
[See your IGF-1 trend in protocol context →](/auth)
Both forms work. Neither is "better" in the abstract. The right choice depends on your protocol experience, your willingness to commit to monitoring, your daily-injection tolerance, and what your clinician is comfortable supervising.
If you're doing your first GH-axis cycle: no DAC paired with Ipamorelin. Daily, pre-bed, on empty stomach. Track IGF-1 at 6 weeks. This is the protocol with the most predictable risk profile and the most published data.
---
*This article is for informational and educational purposes only. It does not recommend any specific dose or schedule. Both forms of CJC-1295 require a prescription from a licensed provider in the United States as of 2026. Always consult a qualified healthcare provider before starting any peptide protocol. MyProtocolStack is a tracking and education platform — it does not diagnose, treat, or prescribe.*
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers — not generic charts.
Start Free →